This report displays the potential drug interactions for the following 2 drugs:
- Esbriet (pirfenidone)
- Mekinist (trametinib)
Interactions between your drugs
No interactions were found between Esbriet and Mekinist. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Esbriet
A total of
230 drugs
are known to interact with
Esbriet.
Mekinist
A total of
30 drugs
are known to interact with
Mekinist.
Drug and food interactions
Pirfenidone should be taken with food to help reduce dizziness and gastrointestinal side effects such as diarrhea, nausea, vomiting, and upset stomach. Avoid smoking during treatment, as cigarette smoking can reduce the blood levels and effects of pirfenidone. If you are a smoker, you should try to quit smoking before starting treatment. Talk to your doctor or pharmacist if you have any questions or concerns, or need help in finding a smoking cessation program. You should also avoid consuming grapefruit or grapefruit juice while taking pirfenidone, as it may increase blood levels of the medication and lead to more side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food may delay and reduce the absorption of trametinib, which may lead to lower blood levels of the medication and possibly reduced effectiveness. You should take trametinib at least 1 hour before or 2 hours after a meal.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
